ZLJ-6
ZLJ-6 is a dual COX and 5-LOX inhibitor with oral activity. The IC50 values for COX-1, COX-2 and 5-LOX were 0.73, 0.31 and 0.99 μM, respectively. ZLJ-6 has anti-inflammatory and analgesic activity.
For research use only. We do not sell to patients.
- CAS No.: 1051931-39-5
- Formula: C13H17N3O6S2
- Molecular Weight:375.42
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
COX-1 0.73 μM (IC50) |
COX-2 0.31 μM (IC50) |
5-LOX 0.99 μM (IC50) |
ZLJ-6 (3, 10, 30 μM, 6 h) can effectively inhibit the expression of TNF-α-induced monocyte endothelial interaction and adhesion molecules (e-selectin, ICAM-1 and VCAM-1)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HUVECs
-
Concentration:3, 10, 30 μM
-
Incubation Time:6 h
-
Result:Decreased NF-κB p65 subunit translocation to nucleus dose-dependently.
Inhibited TNF-α-induced IκBα phosphorylation.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1051931-39-5
-
Molecular Weight 375.42
-
Formula C13H17N3O6S2
-
SMILES
CS(=O)(O)=O.CN(C(N)=NC/1=O)C1=C/C2=CC=C(C=C2)S(C)(=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Chen L, et al. ZLJ-6, a novel COX/5-LOX inhibitor, attenuates TNF-α-induced endothelial E-selectin, ICAM-1 and VCAM-1 expression and monocyte-endothelial interactions via a COX/5-LOX-independent mechanism. Vascul Pharmacol. 2011 Nov-Dec;55(5-6):135-42. [Content Brief]
[2]. Li L, et al. The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor. Eur J Pharmacol. 2009 Apr 1;607(1-3):244-50. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)